ImmuneMed Inc. promises to become a world-trusted company based on creative high-tech intensive research and sound management. Our mission is on human health and welfare in terms of the treatment of incurable or obstinate diseases.
We believe that the human immune system itself is the most effective defense system of our body against various infectious diseases. These beliefs have been a guiding principle for our research over the years. Using the innate immune system, a new antiviral cytokine has been developed and the research has been done using various techniques, such as virus culture, protein purification, RT-PCR, gene cloning, ELISA, and MALDI-TOF spectrometry for protein expression in conjunction with animal experiments.
In addition, we have been also developing a variety of diagnostic kits using lateral flow immunochromatographic technology for early detection of acute febrile illnesses such as Scrub typhus, Leptospirosis, Hemorrhagic fever with renal syndrome, and Dengue fever.
Virus Suppressing Factor (VSF)
Our company is determined to develop noble or innovative products related to infectious diseases. Over the past 20 years, we have discovered a highly active antiviral substance called VSF (Virus Suppressing Factor).
Although there are several antiviral drugs currently available in the market, it turned out to be true that synthetic chemicals and interferon have many limitations in their usage as proper antiviral agents. The use of synthetic pharmaceuticals has shown a problem of increasing resistance, and interferon, even with its broad spectrum, still has limitations due to its weak activity. Like interferon, VSF is also produced in the body, but when VSF’s antiviral activity was tested in animal experiments, it shows much more potent antiviral activity than any other antiviral cytokine such as interferon. We believe that development of VSF as an antiviral therapeutic is the best way to overcome the limitations of existing synthetic pharmaceuticals and interferon.
VSF is expected to cure the viral diseases currently classified as incurable or obstinate; therefore it is expected to have unlimited market potential. It has been currently known that the current market for interferon in the world is estimated to be 11 billion USD. The possibility of success for VSF in clinical trials should be very high due to its origin in the living organism. On the contrary, the possibility of success for synthetic pharmaceuticals in clinical trials is less than 1%.
VSF is a protein consisting of composite materials. Developed countries like the USA have started realizing the potential of composite materials possessing promising results.
A number of possibilities of their good effectiveness have been discussed in various research papers, but the methods to obtain such substances are yet in the elementary stage. According to several reports, when serum from a monkey infected with the AIDS virus showing no symptoms, was treated with cells from another monkey infected with AIDS showing apparent symptoms, the AIDS virus perished. Scientists started to realize this clearance is mainly due to the composite proteins secreted from T-Lymphocyte of the monkey infected with the AIDS virus showing no symptom.
We have been pursuing these concepts for several years and have reached a level where we can identify and characterize such materials. We are now working to develop a novel therapeutic substance. The development of antivirals based on these concepts goes into advance by our company at least 5 years earlier than those of the rest of world. We expect to announce VSF as a new antiviral therapeutic agent on the world antiviral market by 2019.
Acute Febrile Illness(AFI) Diagnostic Kit
Acute febrile illnesses (Scrub typhus, Leptospirosis, and Haemorrhagic fever with renal syndrome) are widely spreading infectious diseases in the world. These infections occur in Korea (around 100,000 people per year), Southeast Asia, and China, causing epidemics particularly in autumn. More than 10 million people are estimated to be infected infected worldwide annually. The main victims of these infections are people dwelling in the wilds, such as farmers, soldiers, and hikers.
Because of conventional diagnostic limitations, prolonged fever of AFI sometimes leads to the death of patients.
Since a different treatment should be applied to each disease, rapid and accurate early diagnosis is urgently needed to distinguish a certain disease from various diseases with similar symptoms. It is impossible to differentiate each disease clinically. Therefore, it is necessary to develop specific and sensitive serological diagnosis. For the past 10 years, we have focused on developing a rapid, accurate, and reproducible AFI diagnostic kit with high sensitivity and specificity. We recently launched a new AFI kit that simultaneously detects both IgM and IgG of 3 different AFIs within 15 mins, based on the lateral flow immunochromatographic assay.
Dengue fever is a mosquito-borne disease that occurs in tropical and subtropical areas of the world. Mild dengue fever causes a high fever, rash, and muscle and joint pain. A severe form of dengue fever, also called dengue hemorrhagic fever, can cause severe bleeding, a sudden drop in blood pressure (shock) and death.
Millions of cases of dengue infection occur worldwide each year. Dengue fever is most common in Southeast Asia and the western Pacific islands, but the disease has been increasing rapidly in Latin America and the Caribbean.
We went into the business of AFI diagnosis and other diagnosis since its diagnostic market potential is good and our diagnostic kit is developed to fit into the world class research standard by our team. Our rapid diagnostic kits have been marketed from 2009 and they can be used in General Hospitals, Clinical Inspection Centers, Rural Health Centers, and Military Clinics worldwide.
We also possess the proprietary materials and technology required for the vaccine development, and we are sure to develop it soon.
|Capital||Number of Shares|
|1,360,216,500 Korea won||2,720,433 shares|